A Biotech's Defining Moment: Rafael Holdings Completes Pivotal Trial for Rare Disease Drug

NEWARK, NJ – June 10, 2026 – In a move that could reshape the therapeutic landscape for a devastating rare disease and catalyze a significant corporate transformation, Rafael Holdings, Inc. today announced the completion of its pivotal Phase 3 TransportNPC™ study. The final patient has concluded their last visit in the trial evaluating Trappsol® Cyclo™, an investigational therapy for Niemann-Pick Disease Type C (NPC), a fatal, progressive genetic disorder. The announcement signals that the company is on track to announce topline results and submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026.

This milestone is more than just a clinical checkpoint; it represents the culmination of a massive global effort and a strategic bet by Rafael Holdings to transition from a diversified holding company into a focused, commercial-stage biopharmaceutical enterprise. For patients and families grappling with NPC, it marks a significant step forward in a long and arduous search for effective treatments.

Hope on the Horizon for a Devastating Disease

Niemann-Pick Disease Type C is often described as a “cellular traffic jam.” Caused by a genetic mutation, the disease prevents the body’s cells from properly transporting cholesterol and other lipids, leading to their toxic accumulation, particularly in the liver, spleen, and brain. The consequences are catastrophic. Symptoms vary widely but relentlessly progress, often including developmental regression, difficulty with coordination and swallowing, cognitive decline, seizures, and ultimately, premature death.

“In a progressive neurodegenerative disease like NPC, the goalposts for success are different,” explained a neurologist familiar with rare disease trials. “For these families, simply halting the progression—achieving stability—is a monumental victory. The prospect of a therapy that could potentially reverse or improve symptoms is what drives this entire field of research.”

Until recently, the treatment landscape was sparse. While the FDA’s approval of two new therapies in late 2024, Miplyffa and Aqneursa, provided new options for managing neurological symptoms, a significant unmet need persists. The completion of the TransportNPC™ trial, the largest and most comprehensive controlled study for an NPC therapy to date, brings a new wave of optimism to this community. The study enrolled 94 patients across 27 sites in 13 countries, reflecting a massive undertaking.

Joshua Fine, Chief Operating Officer of Rafael Holdings, emphasized the collaborative nature of the achievement. “Reaching the conclusion of the pivotal Phase 3 TransportNPC™ trial is a monumental achievement that belongs, first and foremost, to the patients and families, advocacy organizations, and physicians who stood at the heart of this global effort,” he stated. “Together, we have advanced the clinical understanding of NPC, as well as the lived experience of this devastating disease, as we work to deliver a potentially life changing treatment option for a community with significant unmet need.”

The Science and the Regulatory Path

Trappsol® Cyclo™ is a proprietary formulation of hydroxypropyl-β-cyclodextrin (HPβCD), a compound that acts like a molecular sponge. Its mechanism is designed to sequester the trapped cholesterol within cells and facilitate its removal, effectively bypassing the defective cellular machinery that defines NPC. This approach targets the fundamental pathology of the disease.

Confidence in the Phase 3 outcome is bolstered by promising earlier data. A previous Phase 1/2 study showed that nearly 90% of patients experienced improvement in at least two domains of a clinical severity scale. More recently, data from a pediatric sub-study involving patients from birth to three years old was particularly encouraging, with 80% of these young children showing stable or improved scores on the Clinical Global Impression (CGI) scale, with no serious adverse events linked to the drug. This suggests that early intervention could be critical in altering the disease's trajectory.

The regulatory journey for Trappsol® Cyclo™ has been strategically navigated. The therapy has received Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the FDA. These programs are designed to accelerate the development and review of drugs for serious conditions with high unmet needs. The Rare Pediatric Disease designation is especially valuable, as it could grant Rafael Holdings a Priority Review Voucher upon approval, a tradable asset that can be used to expedite the review of another drug.

Further signaling a clear path forward, the company has already completed its pre-NDA meeting with the FDA and received acknowledgement that its U.S. Expanded Access Program (EAP) can proceed. The EAP allows patients with life-threatening conditions who cannot enroll in a clinical trial to gain access to investigational therapies, providing a crucial bridge for the most vulnerable patients while the drug undergoes final review.

A Biotech's Strategic Pivot to Commercialization

The completion of the TransportNPC™ trial is the linchpin in Rafael Holdings' strategic evolution. Following a definitive merger agreement with Cyclo Therapeutics in 2024, Rafael Holdings pivoted to make Trappsol® Cyclo™ its lead clinical program. This move represents a deliberate shift from a company with a portfolio of interests to a focused biotech on the cusp of commercialization.

This high-stakes strategy is aimed squarely at the lucrative but challenging rare disease market. For a company with a market capitalization around $100 million, a successful launch of an orphan drug could be transformative.

Howard Jonas, CEO and Chairman of Rafael Holdings, framed the milestone in clear business terms. “Having already completed our pre-NDA meeting with the FDA, we believe we have a clear and expedited path forward reflective of the urgency and unmet need in NPC and expect to submit our NDA in the second half of 2026,” he said. “NPC represents a high-unmet-need market, positioning Rafael Holdings to potentially unlock substantial, long-term value for our shareholders as we work toward transitioning Rafael Holdings into a commercial-stage biotechnology company.”

The coming months will be critical. The investment community, medical professionals, and patient families will all be keenly awaiting the topline data expected later this year. Those results will determine the next chapter for Trappsol® Cyclo™ and will serve as the ultimate validation of Rafael Holdings’ bold strategic pivot.